{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=91", "query": { "condition": "Multiple Cancers", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 4778, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T09:44:10.491Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03068351", "title": "Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "RO6870810", "type": "DRUG" }, { "name": "daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2017-06-26", "completion_date": "2019-08-01", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 8, "location_summary": "Duarte, California • Stanford, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068351" }, { "nct_id": "NCT02744612", "title": "Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 39, "start_date": "2016-07-01", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Columbus, Ohio", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744612" }, { "nct_id": "NCT03091192", "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Carcinoma, Renal Cell", "Kidney Neoplasms", "Urologic Neoplasms", "Kidney Diseases", "Neoplasms by Site", "Enzyme Inhibitors", "Protein Kinase Inhibitors" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 60, "start_date": "2017-07-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 8, "location_summary": "La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091192" }, { "nct_id": "NCT02462187", "title": "Topical NVN1000 for the Treatment of External Genital and Perianal Warts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genital Warts", "Perianal Warts" ], "interventions": [ { "name": "NVN1000 8% Gel", "type": "DRUG" }, { "name": "NVN1000 16%", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" }, { "name": "NVN1000 24%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 108, "start_date": "2015-06-12", "completion_date": "2016-10-17", "has_results": true, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 15, "location_summary": "Fountain Valley, California • Lomita, California • San Diego, California + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02462187" }, { "nct_id": "NCT05363111", "title": "Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Actinium Ac 225-DOTA-Daratumumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Indium In 111-DOTA-Daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-11-22", "completion_date": "2027-03-23", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363111" }, { "nct_id": "NCT05983198", "title": "Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "225Ac-PSMA-R2", "type": "DRUG" }, { "name": "68Ga-PSMA-R2", "type": "RADIATION" }, { "name": "68Ga-PSMA-11", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 33, "start_date": "2023-11-07", "completion_date": "2031-03-04", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05983198" }, { "nct_id": "NCT01364363", "title": "Unrelated Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Severe Aplastic Anemia", "Paroxysmal Nocturnal Hemoglobinuria", "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Syndromes", "Chronic Myelogenous Leukemia", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Multiple Myeloma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Large Granulocytic Leukemia" ], "interventions": [ { "name": "Allogeneic transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 64, "start_date": "2005-03", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2022-11-23", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364363" }, { "nct_id": "NCT01182233", "title": "Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Total Skeletal Irradiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2010-06", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182233" }, { "nct_id": "NCT02027428", "title": "Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Abraxane (Induction)", "type": "DRUG" }, { "name": "Carboplatin (Induction)", "type": "DRUG" }, { "name": "Abraxane (Maintenance)", "type": "DRUG" }, { "name": "Best Supportive Care (Maintenance)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 427, "start_date": "2014-02-11", "completion_date": "2019-08-01", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 91, "location_summary": "Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027428" }, { "nct_id": "NCT05144334", "title": "A Study of BTX-1188 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Hodgkin Lymphoma", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "BTX-1188", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotheryx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-01-24", "completion_date": "2023-09-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-09T09:44:10.491Z", "location_count": 4, "location_summary": "Duarte, California • New York, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144334" } ] }